Prospectus, September 9, 1975

ELECTION OPENS TODAY; PC news in brief: Baseball trip…., Wind and Strings…., Hot Meals…., IOC…., Review Basics….; Bus Arrives; editorials; Aid for the blind; Letters To The Editor; Blacker\u27s Block; Letter to all men born in 1957; Twilight tours offered by PC land lab; Land Lab open house; Parking spaces available!; Womens Sports; Good News; Meeting to discuss Stu-Go elections; Women\u27s Column; Newman Club meets today; Good news!; Maximum Sex; Parkland College Pizza Eating Contest; Bible study anyone?; 30 new faculty start at P.C.; Vinyl Love; Speech Anyone?; IM trophies to be awarded; Campus near capacity? Enrollment up; Skylines; Enrollment In woman\u27s program; Classified; Sports Views; Unk Blacker: Dirt Track Wizard; Grothe has two lettermen as linksters open season; Intramural Sign-Up; Fast Freddy\u27s football forecast; Lynette Trout to coach all women sports; Games Of September 13; \u27December 1 or bust\u27 cry latest on PE completion; SNA wants new members; Farout Planethttps://spark.parkland.edu/prospectus_1975/1007/thumbnail.jp

Prospectus, October 7, 1975

$10,000 FOUND; Special Election To Be Set; Custom Crunch; PC News in Brief, Nurse\u27s Course, Apologies, Dance; Club Notes: Lit. Magazine…, Veterans\u27 Affairs; editorials; Letters To The Editor; Roots & Radicals; Pia\u27s Promises Parkland Low Prices; The Kaleidoscope; Dear Bonnie; Good News; Distaff Side; Parkland Math Teachers Also Authors; A Tom Swift Story; Sports Views; Football: Yes of No?????; Parkland Cross Country, U of I clash; Intramurals: The People\u27s Sportl Football: Men\u27s I.M. Football Schedule; Coaches\u27 Corner; Football Results; Jocks; womensports; Baseball Team has last fall practice; Fast Freddy Winners Announced; Fast Freddy\u27s football forecast; Computers Reproduce; Stu-Go Fiscal Budget Approved; Images; Foto-Funny\u27s; Vinyl Love; Mini-Concert Series Opens; Country Bouquet; Living on Borrowed Sunlight; Energy and Automation; Classified; A Lease that lets you Sleep; Far Out Planet; Skylines; Back to Basics - Eng 100 Evaluatedhttps://spark.parkland.edu/prospectus_1975/1005/thumbnail.jp

Prospectus, November 18, 1975

PC NEWS IN BRIEF: TOYS FOR TOTS, SHOPPING TRIP, KARATE, LOU HENSON, CHEERLEADERS, BIO 200; Hurry, 3 days remain; IKE…What?; Off Campus offering; P.C. Women 4th in State; editorial; Roots & Radicals; Far Out Planet; Letter To The Editor; Student Achievement Recognition Award; Some - Dancers?; Stick it in your...; P.M. Student Coffee Hour; Tickets Available; Aides to host tea For C-U Teachers; Introducing, Wes Crum; Distaff Side; \u27Why can\u27t we be friends?\u27; Dog Wash; EA to meet; First Meeting; Photo Contest; ERA Rally Held; (IBEA) Meeting Held; Good News; Louisiana Funk at its greatest; Purlie; Furor shakes up Stu-Go; Cited for misconduct: Three members suspended; Discord within Stu-Go: Conference under fire; Finance Board not doing job; Alternatives to Stu-Go; McMullen Resigns; Gameroom Brings Big money; Broken Record?; StuGo States Pinball Project Progresses; Skylines: Black holes?; Parkland Events; Students Not Fascists; Vinyl Love; B and O preforms; Country Bouquet: The Grand Ole Opry ; Dear Bonnie; Classified; Moondogs demolish Wrecks; Fast Freddy\u27s football forecast; I.M. Basketball starts today; Basketball schedule; Games of November 22; Coach\u27s Corner; Parkland Athletes Earn International Acclaim; Karate Demo set for Nov. 20; Ken needs you; Sports Views; Blackhawks vs Broadstreet Bullies at Chicago Stadiumhttps://spark.parkland.edu/prospectus_1975/1002/thumbnail.jp

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Item does not contain fulltextThe primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MTD) of the potent and selective Aurora B kinase inhibitor barasertib (AZD1152) in patients with newly diagnosed or relapsed acute myeloid leukemia (AML). Part A determined the MTD of barasertib administered as a continuous 7-day infusion every 21 days. In part B, the efficacy of barasertib was evaluated at the MTD. In part A, 32 patients were treated with barasertib 50 mg (n = 3), 100 mg (n = 3), 200 mg (n = 3), 400 mg (n = 4), 800 mg (n = 7), 1200 mg (n = 6), and 1600 mg (n = 6). Dose-limiting toxicities (stomatitis/mucosal inflammation events) were reported in the 800 mg (n = 1), 1200 mg (n = 1), and 1600 mg (n = 2) groups. The MTD was defined as 1200 mg. In part B, 32 patients received barasertib 1200 mg. In each part of the study, 8 of 32 patients had a hematologic response according to Cheson AML criteria. The most commonly reported grade >/= 3 events were febrile neutropenia (n = 24) and stomatitis/mucosal inflammation (n = 16). We concluded that the MTD of barasertib is 1200 mg in patients with relapsed or newly diagnosed AML. Toxicity was manageable and barasertib treatment resulted in an overall hematologic response rate of 25%. This study is registered at www.ClinicalTrials.gov as NCT00497991

Health-status outcomes with invasive or conservative care in coronary disease

BACKGROUND In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients. METHODS We assessed angina-related symptoms, function, and quality of life with the Seattle Angina Questionnaire (SAQ) at randomization, at months 1.5, 3, and 6, and every 6 months thereafter in participants who had been randomly assigned to an invasive treatment strategy (2295 participants) or a conservative strategy (2322). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate differences between the treatment groups. The primary outcome of this health-status analysis was the SAQ summary score (scores range from 0 to 100, with higher scores indicating better health status). All analyses were performed in the overall population and according to baseline angina frequency. RESULTS At baseline, 35% of patients reported having no angina in the previous month. SAQ summary scores increased in both treatment groups, with increases at 3, 12, and 36 months that were 4.1 points (95% credible interval, 3.2 to 5.0), 4.2 points (95% credible interval, 3.3 to 5.1), and 2.9 points (95% credible interval, 2.2 to 3.7) higher with the invasive strategy than with the conservative strategy. Differences were larger among participants who had more frequent angina at baseline (8.5 vs. 0.1 points at 3 months and 5.3 vs. 1.2 points at 36 months among participants with daily or weekly angina as compared with no angina). CONCLUSIONS In the overall trial population with moderate or severe ischemia, which included 35% of participants without angina at baseline, patients randomly assigned to the invasive strategy had greater improvement in angina-related health status than those assigned to the conservative strategy. The modest mean differences favoring the invasive strategy in the overall group reflected minimal differences among asymptomatic patients and larger differences among patients who had had angina at baseline

Initial invasive or conservative strategy for stable coronary disease

BACKGROUND Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. METHODS We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. A key secondary outcome was death from cardiovascular causes or myocardial infarction. RESULTS Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurred in the conservative-strategy group. At 6 months, the cumulative event rate was 5.3% in the invasive-strategy group and 3.4% in the conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to 3.0); at 5 years, the cumulative event rate was 16.4% and 18.2%, respectively (difference, 121.8 percentage points; 95% CI, 124.7 to 1.0). Results were similar with respect to the key secondary outcome. The incidence of the primary outcome was sensitive to the definition of myocardial infarction; a secondary analysis yielded more procedural myocardial infarctions of uncertain clinical importance. There were 145 deaths in the invasive-strategy group and 144 deaths in the conservative-strategy group (hazard ratio, 1.05; 95% CI, 0.83 to 1.32). CONCLUSIONS Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years. The trial findings were sensitive to the definition of myocardial infarction that was used